{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(4)"],"submitter":["Drexler Y"],"pubmed_abstract":["<h4>Introduction</h4>Dysregulation of sphingolipid and cholesterol metabolism contributes to the pathogenesis of glomerular diseases (GDs). Apolipoprotein M (ApoM) promotes cholesterol efflux and modulates the bioactive sphingolipid sphingosine-1-phosphate (S1P). Glomerular ApoM expression is decreased in patients with focal segmental glomerulosclerosis (FSGS). We hypothesized that glomerular ApoM deficiency occurs in GD and that ApoM expression and plasma ApoM correlate with outcomes.<h4>Methods</h4>Patients with GD from the Nephrotic Syndrome Study Network (NEPTUNE) were studied. We compared glomerular mRNA expression of ApoM (gApoM), sphingosine kinase 1 (SPHK1), and S1P receptors 1 to 5 (S1PR1-5) in patients (<i>n</i> = 84) and controls (<i>n</i> = 6). We used correlation analyses to d"],"journal":["Kidney international reports"],"pagination":["884-897"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10105063"],"repository":["biostudies-literature"],"pubmed_title":["Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease."],"pmcid":["PMC10105063"],"pubmed_authors":["Contreras G","Ma R","Fornoni A","Kurano M","Elfassy T","Christoffersen C","Mariani LH","Molina J","Merscher S","Drexler Y","Yatomi Y"],"additional_accession":[]},"is_claimable":false,"name":"Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease.","description":"<h4>Introduction</h4>Dysregulation of sphingolipid and cholesterol metabolism contributes to the pathogenesis of glomerular diseases (GDs). Apolipoprotein M (ApoM) promotes cholesterol efflux and modulates the bioactive sphingolipid sphingosine-1-phosphate (S1P). Glomerular ApoM expression is decreased in patients with focal segmental glomerulosclerosis (FSGS). We hypothesized that glomerular ApoM deficiency occurs in GD and that ApoM expression and plasma ApoM correlate with outcomes.<h4>Methods</h4>Patients with GD from the Nephrotic Syndrome Study Network (NEPTUNE) were studied. We compared glomerular mRNA expression of ApoM (gApoM), sphingosine kinase 1 (SPHK1), and S1P receptors 1 to 5 (S1PR1-5) in patients (<i>n</i> = 84) and controls (<i>n</i> = 6). We used correlation analyses to d","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-04T08:29:06.625Z","creation":"2025-04-04T08:29:06.625Z"},"accession":"S-EPMC10105063","cross_references":{"pubmed":["37069998"],"doi":["10.1016/j.ekir.2023.01.031"]}}